Alagille Syndrome
Conference Roundup
Progressive Familial Intrahepatic Cholestasis

Long-term benefits of maralixibat in PFIC demonstrated in 2-year study

Posted on

Maralixibat (MRX) demonstrates significant and sustained improvements in pruritus, serum bile acids (sBA), total bilirubin (TB), and growth in patients with progressive familial intrahepatic cholestasis (PFIC) over a 2-year period, according to a study presented at The Liver Meeting 2023. The study suggests that MRX treatment contributes to overall improved liver health across a broad range of genetic PFIC types and can be effectively maintained long-term.

Maralixibat has shown promising results in the 26-week MARCH Phase 3 study.

In the MARCH-ON study, an open-label, long-term extension of MARCH, researchers evaluated the long-term effects of MRX in 2 groups: those initially randomized to MRX in MARCH (MRX-MRX group) and those who received a placebo in MARCH and switched to MRX in MARCH-ON (PBO-MRX group).

Results from the MRX-MRX group demonstrated sustained improvements in pruritus, sBA, tb, and growth over the 2-year period. Notably, significant improvements observed in the first 26 weeks of the MARCH study were maintained through Week 104 in MARCH-ON. The PBO-MRX group also showed substantial improvements, aligning with observations from the initial MARCH MRX group.

Key findings include a reduction in pruritus, sBA, and TB, as well as positive growth outcomes in both groups. No new safety concerns were identified, with gastrointestinal-related adverse events being the most common, primarily mild and transient diarrhea.

Arikan C and Ovchinsky N. Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): 2-year data from the MARCH-ON study. Presented at: The Liver Meeting 2023.

Rare Disease 360® is the Official Media Partner and Official Publication of The Alagille Syndrome Alliance (Alagille.org).